Efficacy and Safety of Celecoxib for Treatment of Mild to Moderate Postpartum Depression: A Randomized, Double-Blind, Placebo-Controlled Trial Publisher Pubmed



Esalatmanesh S^{1, 2} ; Kashani L¹ ; Khooshideh M¹ ; Moghaddam HS² ; Ansari S³ ; Akhondzadeh S² Show Affiliations
Source: Archives of Gynecology and Obstetrics Published:2024

Abstract

Purpose: Evidence has demonstrated the roles of inflammatory processes in pathogenesis of depression. We aim to assess the effects of adjunctive celecoxib with cognitive behavioral therapy (CBT), an anti-inflammatory agent, in treatment of postpartum depression and on levels of Brain-derived neurotrophic factor (BDNF) and inflammatory cytokines. Methods: This was a randomized, double-blind, placebo-controlled trial to investigate the effects of adjunctive celecoxib with CBT on postpartum depression. Fifty outpatient women with postpartum depression, participated in this study. Patients randomly received either a celecoxib capsule twice a day or a placebo capsule twice a day for 6 weeks. Patients were assessed using the Hamilton Depression Rating Scale (HDRS) and the adverse event checklist at baseline and weeks 2, 4, and 6. Results: Patients in the celecoxib group showed a greater decline in HDRS scores from baseline to all three study time points compared to the placebo group (p = 0.12 for week 2, p = 0.001 for week 4, p < 0.001 for week 6). Rate of response to treatment was significantly higher in the celecoxib group compared to the placebo group at week 4 (60 vs 24%, p = 0.010) and week 6 (96 vs 44%, p < 0.001). Rate of remission was significantly higher in the celecoxib group compared to the placebo group at week 4 (52 vs 20%, p = 0.018) and week 6 (96 vs 36%, p < 0.001). Levels of most inflammatory markers were significantly lower in the celecoxib group compared to the placebo group at week 6. Levels of BDNF were significantly higher in the celecoxib group compared to the placebo group at week 6 (p < 0.001). Conclusions: Findings suggest adjunctive celecoxib is an effective treatment for the improvement of postpartum depressive symptoms. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023.